

Diagonal Bio AB has signed a distribution agreement with Techtum Lab AB

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed a distribution agreement with Techtum Lab AB ("Techtum Lab"). Techtum Lab is granted the rights to distribute Diagonal Bio's analytical instrument, LAMPlify®, in Sweden until May 30, 2025, with an option for a 12-month renewal. This collaboration was initiated by a first critical milestone in the pilot study which started in November 2023.

Diagonal Bio communicated in November 2023 that the Company initiated a pilot study with Techtum Lab, a full-service partner for molecular biology laboratories in the Nordic region. The pilot study involved the identification of genetic markers for herpesvirus types 1 and 4 as well as influenza virus in horses and was conducted in a veterinary laboratory in the Stockholm area. The first critical milestone of the pilot study has solidified the foundation for this distribution partnership, which highlights the benefits of Diagonal Bio's analytical technology.

The signed agreement stipulates distribution rights in Sweden until May 30, 2025, with an option for a 12-month renewal at the end of the term. The distribution agreement is non-exclusive and allows Techtum Lab to introduce Diagonal Bio's product, LAMPlify®, to potential clients in other Nordic countries which increases Diagonal Bio's reach. This underscores Diagonal Bio's commitment to innovation in the field of molecular analyses.

"Our partnership with Techtum Lab underscores the potential of our analytical technology. By uniting our strengths, we aim to deliver value to the Nordic biotechnology market. This is a landmark moment for Diagonal Bio as we advance our analytical technologies" - Karin Wehlin, Interim CEO of Diagonal Bio AB (publ).

"The solid performance of Diagonal Bio's LAMPlify® instrument in our collaborative pilot study has led us to this agreement. We're excited about the future and the impact our cooperation will have on advancing analytics" - Ulrica Karlsson, CEO of Techtum Lab AB.

För ytterligare information om Diagonal Bio AB, vänliga kontakta

Karin Wehlin, t.f. VD

Telefon: +46 703 052 488

E-post: kw@diagonalbio.com

www.diagonalbio.com

Kerstin Åkesson Jakobsson

Styrelse Ordförande

Telefon: +46 705 504 540

Epost: kj@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-post: ca@skmg.se

Denna information är sådan information som Diagonal Bio AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 16 feb 2024.

Diagonal Bio AB grundades 2020 och är ett svenskt bioteknikbolag med säte och kontor i Lund. Bolaget utvecklar plattformen Panviral för att detektera och diagnostisera små sektioner av patogengenom, exempelvis virus, bakterier och svampar. Bolaget grundades med målsättningen att minska mänskligt lidande genom att med egenutvecklad teknik revolutionera global diagnostik av patogenburna sjukdomar. Diagonal Bios patenterade teknologi kan även användas för de mindre reglerade marknadssegmenten via LAMPlify™.